Search Results - "Hay, Joel"

First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective by Hu, Xiaohan, Hay, Joel W.

“…•The ICER of pembrolizumab vs. chemotherapy is £86,913/QALY in untreated NSCLC patients•The ICER of pembrolizumab is sensitive to patient utility other than…”
Get full text

Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling by Hay, Joel W.

“…In contrast to many other countries, during the 20 years since the founding of Value in Health, the United States has moved further away from using value-based…”
Get full text

Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial by Meeker, Daniella, Linder, Jeffrey A, Fox, Craig R, Friedberg, Mark W, Persell, Stephen D, Goldstein, Noah J, Knight, Tara K, Hay, Joel W, Doctor, Jason N

“…IMPORTANCE: Interventions based on behavioral science might reduce inappropriate antibiotic prescribing. OBJECTIVE: To assess effects of behavioral…”
Get full text

Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function by Salcedo, Jonathan, Hay, Joel W., Lam, Jenny

“…Nonvalvular atrial fibrillation (NVAF) is highly prevalent and increases the risks of cardiovascular events. In a recent subgroup analysis, treatment response…”
Get full text

A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L by Hay, Joel W., Gong, Cynthia L., Jiao, Xiayu, Zawadzki, Nadine K., Zawadzki, Roy S., Pickard, A. Simon, Xie, Feng, Crawford, Samuel A., Gu, Ning Yan

“…Background The COVID-19 pandemic has resulted in negative impacts on the economy, population health, and health-related quality-of-life (HRQoL). Objective To…”
Get full text

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments by Messali, Andrew, Villacorta, Reginald, Hay, Joel W.

“…Grade IV glioma (glioblastoma) is one of the most common brain/central nervous system cancers. In 2005, the standard of care for adjuvant treatment was…”
Get full text

Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US by Yu, Tianzhou, Chen, Jiafan, Gu, Ning Yan, Hay, Joel W, Gong, Cynthia L

“…Online longitudinal surveys may be subject to potential biases due to sample attrition. This study was designed to identify potential predictors of attrition…”
Get full text

Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection by Chen, Jiahe, Gong, Cynthia L., Hitchcock, Matthew M., Holubar, Marisa, Deresinski, Stanley, Hay, Joel W.

“…Treatment of Clostridioides difficile infection (CDI) has undergone significant change in recent years with the introduction of fidaxomicin and bezlotoxumab…”
Get full text

A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men by Drabo, Emmanuel F., Hay, Joel W., Vardavas, Raffaele, Wagner, Zachary R., Sood, Neeraj

“…Background. Substantial gaps remain in understanding the trade-offs between the costs and benefits of choosing alternative human immunodeficiency virus (HIV)…”
Get full text

Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants by Ganapathy, Vaidyanathan, Hay, Joel W, Kim, Jae H

“…This study evaluated the cost-effectiveness of a 100% human milk-based diet composed of mother's milk fortified with a donor human milk-based human milk…”
Get more information

Validating the Importance of Positive Childhood Experiences on Adult Mental Health by Gong, Cynthia L, Yieh, Leah, Hay, Joel W

Get more information

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States by Cho, Sang Kyu, Hay, Joel W., Barzi, Afsaneh

“…Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks,…”
Get full text

A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma by Lam, Jenny, Hay, Joel W., Salcedo, Jonathan, Kenyon, Nicholas J.

“…Introduction: Poorly controlled severe eosinophilic asthma is difficult and costly to manage. Reslizumab, an add-on treatment for adults with severe…”
Get full text

The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding by Gong, Cynthia L, Zawadzki, Nadine K, Hay, Joel W

Get more information

Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis by Jiao, Xiayu, Hay, Joel W., Sadeghi, Sarmad, Barzi, Afsaneh

“…Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with…”
Get full text

Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis by Zhang, Xinke, Hay, Joel W., Niu, Xiaoli

“…Objective The aim of the study was to compare the cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and intramuscular (IM) interferon (IFN)-β…”
Get full text

Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis by Gong, Cynthia L., Zangwill, Kenneth M., Hay, Joel W., Meeker, Daniella, Doctor, Jason N.

“…ABSTRACT Background Behavioral economics interventions have been shown to effectively reduce the rates of inappropriate antibiotic prescriptions for acute…”
Get full text

Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States by Chen, Christina X, Hay, Joel W

“…Abstract Background/objectives Familial hypercholesterolemia (FH) is a genetic disorder that leads to premature heart disease or stroke if untreated. Statins…”
Get full text

Cost‐Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‐Severe Crohn's Disease in Biologic‐Naïve Patients by Aliyev, Elmar R., Hay, Joel W., Hwang, Caroline

“…Study Objective Ustekinumab was recently approved by the United States U.S. Food and Drug Administration for the treatment of Crohn's disease. In this…”
Get full text

Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey by Thompson, Christin Ann, BS, Hay, Joel W., PhD

“…Abstract Purpose More research is needed on the health effects of marijuana use. Results of previous studies indicate that marijuana could alleviate certain…”
Get full text